Peptide Therapy in 2026: Evidence-Based Options for Recovery & Anti-Aging

Walk into any conversation about anti-aging right now and someone will mention peptides. Recovery peptides, growth-hormone peptides, NAD+, GHK-Cu, BPC-157. The labels are everywhere. The actual evidence, regulation, and supervision standards behind them are not always so clear.

That gap matters. Peptides are not a single drug class. They are short chains of amino acids, and a few dozen of them are used in legitimate clinical settings under careful supervision. Many more are sold through gray-market channels with no FDA review and no quality control. The line between the two is exactly where this guide lives.

If you are looking for a starting point on what peptides actually are, which ones have human data, what the FDA has said about compounding in 2023–2024, and how a supervised program at a medical clinic should look, this is the page to read first. For deeper reading on the most-Googled compound that is not on our service menu, see our educational guide to BPC-157.

The short version: Peptide therapy uses short amino-acid chains to support recovery, hormone balance, sleep, skin, and metabolic health. A small number of peptides — including NAD+, Ipamorelin, Sermorelin, CJC-1295, Tesamorelin, and GHK-Cu — have meaningful human data and are used by licensed clinicians. Others, including BPC-157 and TB-500, are not FDA-approved and were placed on the FDA’s restricted compounding category in 2023. At OC Weight Loss and Medspa we offer Ipamorelin, NAD+, and our GLOW Blend under medical supervision; we do not provide BPC-157 or TB-500.

What’s in this guide

1. What are peptides, exactly?
2. The regulatory landscape (and why it matters)
3. Peptides used in legitimate clinical settings
4. Peptides circulating online we do not recommend
5. What our peptide program looks like
6. Who is a candidate and who isn’t
7. Cost & what supervision should include
8. Risks and side effects
9. How to get started
10. FAQ

What are peptides, exactly?

A peptide is a short chain of amino acids — typically between 2 and 50 amino acids long. Anything longer than about 50 is generally called a protein. Peptides act as biological signals: they bind to receptors, trigger hormone release, modulate inflammation, or instruct cells to make collagen.

Many peptides occur naturally in the body. Insulin, oxytocin, glucagon, and growth hormone–releasing hormone (GHRH) are all peptides. Synthetic peptides used in medicine are designed to mimic, extend, or refine the action of those natural signals. GLP-1 receptor agonists like semaglutide and tirzepatide are peptide medications too — they are simply approved through the standard FDA new-drug pathway, which gives them a different regulatory status than the compounded peptides discussed in this guide.

The peptides marketed in wellness and longevity contexts fall into a few functional buckets:

• Growth-hormone secretagogues — Ipamorelin, Sermorelin, CJC-1295, Tesamorelin. They prompt the pituitary to release more of your own growth hormone.
• Metabolic / mitochondrial — NAD+ (technically a coenzyme, often grouped with peptides in clinic menus), and related precursors.
• Skin and pigment — GHK-Cu (copper peptide), melanotan analogues.
• Repair / anti-inflammatory (gray market) — BPC-157, TB-500. These do not have FDA approval and have been the focus of recent regulatory action.

The regulatory landscape (and why it matters)

This is the part most marketing pages skip. It is also the part that determines whether the peptide you are considering is legal to receive in a U.S. medical setting.

FDA-approved peptide drugs — insulin, semaglutide, tirzepatide, tesamorelin (Egrifta) — have gone through standard new-drug review. Pharmacies fill them as prescriptions, and they are dispensed as named-manufacturer products.

Peptides like Ipamorelin, Sermorelin, and GHK-Cu are not approved as named-manufacturer drugs. They reach patients through 503A compounding pharmacies, which are state-licensed pharmacies that prepare custom medications for individual patients with a valid prescription. Section 503A of the Federal Food, Drug, and Cosmetic Act allows this, but the substances must appear on the FDA’s accepted list (the “503A bulks list”) or have a USP monograph.

In September 2023, the FDA’s Pharmacy Compounding Advisory Committee reviewed a number of peptides, and the agency placed several — including BPC-157, thymosin beta-4 (TB-500), and Ipamorelin in some classifications — into Category 2, meaning the FDA had identified significant safety risks and recommended that they not be compounded under 503A pending further review. Industry guidance and many compounding pharmacies updated their offerings in response. The full list and ongoing updates are tracked through the FDA’s 503A bulk-substances guidance page.

The practical takeaway: just because a clinic offers a peptide does not mean it has cleared U.S. regulatory bar. Reputable clinics work only with licensed compounding pharmacies and only with peptides that remain on accepted compounding lists. Anything you buy online from a “research peptides” vendor is, by definition, sold for laboratory research and not for human use.

Peptides used in legitimate clinical settings

The peptides below are the ones you are most likely to encounter in a medically supervised program in 2026. Each has at least some published human data and is dispensed through compounding pharmacies under prescription.

NAD+ and NAD+ precursors

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme involved in mitochondrial energy production and DNA repair. NAD+ levels decline with age, and a body of preclinical work and small human trials has explored whether boosting NAD+ improves markers of aging, cellular energy, and recovery. Clinics offer NAD+ as IV infusions and as subcutaneous injections; oral precursors (NMN, nicotinamide riboside) are sold as supplements.

The honest evidence picture: there is solid biochemistry behind NAD+ depletion in aging, early-phase human studies of precursors are encouraging for safety and biomarkers, and large outcome trials are still underway. A 2018 review in Cell Metabolism summarized the science and the still-open questions (Rajman et al., 2018). Patients tend to report improvements in energy and clarity; the rigorous outcome data are not yet at the level of, say, a GLP-1 trial. We are honest about that with patients.

Ipamorelin

Ipamorelin is a selective growth-hormone secretagogue. It binds to the ghrelin receptor and prompts the pituitary to release a pulse of natural growth hormone, without significantly raising cortisol or prolactin (which is the issue with older agents like GHRP-6). Reported uses include sleep quality, recovery, lean-mass support, and skin elasticity in adults with age-related GH decline.

Ipamorelin has been studied in clinical-trial settings — for example a randomized study in postoperative ileus (Beck et al., 2014) — though it is not FDA-approved as a finished drug. It is dispensed via compounding pharmacies. Our protocol uses Ipamorelin as a stand-alone evening injection or as part of our GLOW Blend.

Sermorelin and CJC-1295

Sermorelin is a 29-amino-acid GHRH analogue. It was actually FDA-approved in the 1990s for pediatric growth-hormone deficiency under the brand name Geref, though that product has since been discontinued and the molecule is now used through compounding. CJC-1295 is a longer-acting modified GHRH analogue. Both work upstream of Ipamorelin: GHRH drives the pulse, ghrelin agonists amplify it, and many protocols pair them.

For a side-by-side, see Ipamorelin vs Sermorelin — the practical differences come down to half-life, side-effect profile, and what symptom you are targeting (sleep vs. lean mass vs. recovery).

Tesamorelin

Tesamorelin is the one peptide on this list with full FDA approval — it is approved as Egrifta for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. The trial program showed clinically meaningful reduction in visceral adipose tissue (Falutz et al., 2010). Off-label use in a general anti-aging context is occasionally discussed; the proper-use indication is the HIV-related one.

GHK-Cu (copper peptide)

GHK-Cu is a copper-binding tripeptide isolated from human plasma. It has been studied for skin remodeling, wound healing, and hair-follicle support. Most of its established use is topical — a number of legitimate skin-care products contain GHK-Cu — but it is also offered as injection in some clinics. The literature on topical use is reasonable; injectable use is mostly off-label.

Peptides circulating online we do not recommend

Two peptides come up constantly in patient questions and on social media: BPC-157 and TB-500. Neither is on our service menu. Here is the honest reasoning.

BPC-157

BPC-157 is a 15-amino-acid synthetic peptide derived from a fragment of a gastric protein. Animal data — mostly rats — show effects on tendon, ligament, and gut healing, which is the basis for its reputation. Human clinical trial data are essentially absent. It is not FDA-approved for any indication. In the September 2023 FDA Pharmacy Compounding Advisory Committee review, BPC-157 was assigned to Category 2, meaning the agency identified safety concerns sufficient that it should not be compounded under 503A pending further evaluation. As of 2026 it remains outside the accepted compounding framework.

For a fuller treatment of the science, the regulatory status, and what patients should know, see our BPC-157 educational guide. We don’t offer it as a service. We do think patients deserve a sober explanation of what is and isn’t known.

TB-500 (thymosin beta-4 fragment)

TB-500 is marketed as a recovery and tissue-repair peptide. It is a synthetic fragment of thymosin beta-4. Like BPC-157, it has limited human data, no FDA approval, and was reviewed unfavorably by the 2023 FDA advisory committee for compounding. It is also explicitly banned by the World Anti-Doping Agency for athletes. We do not prescribe or compound it.

What our peptide program looks like

At OC Weight Loss and Medspa we offer three categories of peptide therapy under physician supervision:

• NAD+ injections — subcutaneous, typically dosed two to three times a week. Some patients prefer IV infusion for the first loading dose and switch to subcutaneous for maintenance. See NAD+ injections benefits for what to expect in the first month.
• Ipamorelin — subcutaneous, evening dosing, usually 5 nights per week with two off nights to maintain pituitary sensitivity.
• GLOW Blend — our combination protocol focused on skin, recovery, and energy. Composition is reviewed and adjusted with each patient based on labs and goals.

Every peptide protocol begins with a full intake: medical history, medications, current symptoms, baseline labs (typically CBC, CMP, lipids, hormone panel including IGF-1 if a GH-secretagogue is being considered, and sometimes inflammatory markers). Peptides are not started in isolation. They are added when there is a clinical rationale, after we have ruled out simpler explanations for the symptoms a patient came in with.

Follow-up is built into the protocol. We re-check labs at 8–12 weeks, ask about side effects and benefit, and adjust dose or stop if response is not what we expected. Peptide therapy is not a forever-prescription; many patients cycle on and off based on goals.

Who is a candidate — and who isn’t

Reasonable candidates for a supervised peptide program tend to share a few features:

• Adults over 30, more often over 40, with symptoms of age-related decline (sleep quality, recovery, energy, body composition that won’t budge despite training and nutrition)
• Otherwise medically stable, with treatable issues (sleep apnea, thyroid, low testosterone) already worked up
• Willing to commit to lab follow-up and at least a 12-week trial before judging response
• Realistic expectations — peptides modulate, they do not replace fundamentals

People who should not start peptide therapy without much closer evaluation: anyone with a history of cancer (growth-hormone secretagogues are not appropriate when active or recent malignancy is in the picture), uncontrolled diabetes, pregnancy or planned pregnancy, severe cardiovascular disease, or serious liver/kidney impairment. We screen for all of these on intake.

Cost & what supervision should include

Peptide programs vary widely in cost, and a low price almost always reflects either a missing supervision step or a less-reputable compounding source. As a working range in 2026 in Orange County:

• NAD+: $200–$500 per IV infusion; subcutaneous injection programs typically run $300–$600/month for maintenance dosing
• Ipamorelin alone: roughly $250–$450/month depending on dose and pharmacy
• Combination protocols (e.g., GLOW Blend): $400–$700/month
• Initial workup: $200–$500 depending on lab panel

What you should expect for that cost: in-person or telehealth consultation with a licensed provider, baseline and follow-up labs reviewed by a clinician, prescription written and filled at a U.S.-licensed 503A compounding pharmacy, dosing instructions and follow-up schedule, and the ability to reach the clinic with questions. If a program lacks any of those elements — especially the labs and the U.S.-licensed pharmacy — that is a flag.

Risks and side effects

Peptides are generally well tolerated, but they are not risk-free. Common, usually mild effects include:

• Injection-site redness, swelling, or bruising
• Flushing or warmth (more common with NAD+ — slowing the IV rate usually solves it)
• Transient headache, fatigue, or vivid dreams during the first 1–2 weeks
• Mild fluid retention or joint achiness with GH secretagogues
• Increased appetite (ghrelin-receptor agonists like Ipamorelin can do this)

Less common but more serious considerations: sustained elevation of IGF-1 outside the normal range with overuse of GH secretagogues, blood-sugar shifts, and theoretical concerns around stimulating growth in undiagnosed neoplasms. These are why monitoring labs are part of the protocol, not an optional add-on.

Stop-and-call situations: persistent severe headache, vision changes, swelling in one leg, sudden chest pain, or a new lump anywhere. Those warrant urgent evaluation regardless of cause.

How to get started

If you are considering peptide therapy, the order of operations is the same regardless of which clinic you choose:

1. Define what you actually want to change — sleep, recovery, body composition, skin, energy. Different goals point to different peptides.
2. Get baseline labs, ideally reviewed by a clinician who looks beyond “in range” toward optimal patterns for your age and sex.
3. Rule out the cheaper, simpler explanations — thyroid, sleep apnea, low testosterone, vitamin D, iron, cortisol pattern.
4. Pick a clinic that uses U.S.-licensed compounding pharmacies and is willing to talk through the regulatory status of any peptide on its menu.
5. Plan for a 12-week trial, not a 12-day verdict.

Peptide therapy fits into a larger picture. For metabolic goals, a GLP-1 program may be the right starting place. For age-related symptoms in men or women, hormone replacement therapy often deserves evaluation first. Peptides are usually most useful as part of a layered strategy, not as a stand-alone fix.

FAQ

Talk to a clinician at OC Weight Loss and Medspa

If you are weighing whether peptide therapy is appropriate for your goals — or you are already on something and want a sober second opinion — our clinical team in Mission Viejo can review your history, run baseline labs, and tell you honestly whether a supervised peptide program belongs in your plan.

Book a free consultation

Medically reviewed by clinical staff at OC Weight Loss and Medspa. Last updated May 2026.